Remeron Soltab generic approved
Executive Summary
Barr receives approval of generic for Organon's Remeron Soltab (mirtazapine orally disintegrating tablets) on Dec. 17. Barr has 180-day exclusivity and plans to launch the product immediately. Barr was originally sued regarding two patents, but Organon delisted them in April following a ruling regarding Pfizer's Neurontin (gabapentin) which found that patents unrelated to approved uses could not be listed (1"The Pink Sheet" Feb. 3, 2003, p. 20). Barr's exclusivity is based on a patent listed by dosage-form developer Cima, which did not sue. Barr noted that it could be sued over two Organon patents not listed in the "Orange Book"...
You may also be interested in...
Purepac Gabapentin Is “First Generic” After Pfizer Delists Neurontin Patent
Purepac and Ivax will split "first generic" 180-day exclusivity on their versions of Pfizer's antiepileptic Neurontin (gabapentin)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.